A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells

Acta Pharmacologica Sinica

Volumn 25, Issue 10, 2004, Pages 1312-1319

  Liu, Da Chuan ^a,b   Zang, Chuan Bing ^a   Liu, Hong Yu ^a   Possinger, Kurt ^a   Fan, Shao Guang ^b   Elstner, Elena ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Apoptosis; Cell division; Glioblastoma; Peroxisome proliferator activated receptor; TZD18

Indexed keywords

5 [3 [3 (4 PHENOXY 2 PROPYLPHENOXY)PROPOXY]PHENYL] 2,4 THIAZOLIDINEDIONE; CASPASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; TZD 18; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NICK END LABELING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; CASPASE 3; CASPASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GLIOBLASTOMA; HUMANS; PHENYL ETHERS; PPAR ALPHA; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZOLIDINEDIONES; TUMOR SUPPRESSOR PROTEINS;

EID: 5444249738     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
2. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
3. Theocharisa S, Margeli A, Kouraklis G. Peroxisome proliferator activated receptor-gamma ligands as potent antineoplastic agents. Curr Med Chem Anti-Canc Agents 2003; 3: 239-51.
4. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-52.
5. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
6. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-52.
7. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135-9.
8. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-11.
9. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, et al. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74: 155-65.
10. Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98: 71-108.
11. Ng HK, Lam PY. The molecular genetics of central nervous system tumors. Pathology 1998; 30: 196-202.
12. Desai RC, Han W, Metzger EJ, Bergman JP, Gratale DF, MacNaul KL, et al. 5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. Bioorg Med Chem Lett 2003; 13: 2795-8.
13. Desai RC, Gratale DF, Han W, Koyama H, Metzger E, Lombardo VK, et al. Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists. Bioorg Med Chem Lett 2003; 13: 3541-4.
14. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004; 53: 200-8.
15. Zang C, Wachter M, Liu H, Posch MG, Fenner MH, Stadelmann C, et al. Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol 2003; 65: 107-18.
16. Hecker KH, Roux KH. High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR. Biotechniques 1996; 20: 478-85.
17. Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR, et al. Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog 2002; 34: 165-71.
18. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90: 75-80.
19. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000; 83: 1394-400.
20. Abe A, Kiriyama Y, Hirano M, Miura T, Kamiya H, Harashima H, et al. Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol 2002; 436: 7-13.
21. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48-52.
22. Hilding A, Hall K, Skogsberg J, Ehrenborg E, Lewitt MS. Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism. Biochem Biophys Res Commun 2003; 303: 693-9.
23. Hinz B, Brune K, Pahl A. 15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism. Biochem Biophys Res Commun 2003; 302: 415-20.
24. Fehlberg S, Trautwein S, Goke A, Goke R. Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor-gamma, in caspase-dependent and -independent manners. Biochem J 2002; 362: 573-8.
25. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003; 278: 5845-53.
26. Hawcroft G, Gardner SH, Hull MA. Activation of peroxisome proliferator-activated receptor gamma does not explain the antiproliferative activity of the nonsteroidal anti-inflammatory drug indomethacin on human colorectal cancer cells. J Pharmacol Exp Ther 2003; 305: 632-7.
27. Ohta T, Elnemr A, Yamamoto M, Ninomiya I, Fushida S, Nishimura G, et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 2002; 21: 37-42.
28. Elnemr A, Ohta T, Iwata K, Ninomia I, Fushida S, Nishimura G, et al. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 2000; 17: 1157-64.
29. Tsujie M, Nakamori S, Okami J, Takahashi Y, Hayashi N, Nagano H, et al. Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway. Int J Oncol 2003; 23: 325-31.
30. Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, et al. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 2001; 84: 1640-7.
31. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol 1998; 60: 601-17.
32. Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H, et al. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002; 50: 563-7.
33. Li MY, Deng H, Zhao JM, Dai D, Tan XY. PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 2003; 9: 1220-6.
34. Okano H, Shiraki K, Inoue H, Yamanaka Y, Kawakita T, Saitou Y, et al. 15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab Invest 2003; 83: 1529-39.
35. Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 2002; 95: 2243-51.
36. Zander T, Kraus JA, Grammes C, Schlegel U, Feinstein D, Klockgether T, et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 2002; 81: 1052-60.
37. Strakova N, Ehmann J, Dzubak P, Bouchai J, Kolar Z. The synthetic ligand of PPAR{gamma}, ciglitazone, affects human glioblastoma cell lines. J Pharmacol Exp Ther 2004.
38. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC, Lau WY. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 2002; 70: 2631-46.